Place it in its market
Seven layers of its region's market — rates, credit, stress, liquidity, regime, breadth and sectors — with historical precedents. Public example: Apple and ASML.
See how Context works →On the price, the facts of the public record■Insider buy□Insider sell●Results filed
With an account, also○dividends▲splits◌next earningswith an account
End-of-day prices provided by Twelve Data · One close per session; the series does not update during the trading day.
Latest on record
The most recent facts, as filed.
Up to three of the most recent, checkable facts already loaded on this page, each linked to its source.
- Oct 1, 2026Reported sale · Form 4Joshua Hexter, COO & CBO · $135.3KOpen the filing ↗
- Oct 1, 2026Reported sale · Form 4Avraham Gabay, Chief Financial Officer · $90.2KOpen the filing ↗
- Oct 1, 2026Notice of sale · Form 144Avi Gabay · Officer · $93.4KOpen the filing ↗
In numbers
What this profile holds, counted.
Closes · 1 year250
SEC filings on record8496 flagged findings
Reported transactions (Form 4)64since Dec 31, 2025 · and 1 other holding
Corporate events (8-K)30since Aug 9, 2023
What the record says
Description, identity and filings, each with its source.
Every block cites its source. The colour of a finding marks its category — which document, who filed it — not how much it matters.
What the company does
Oramed Pharmaceuticals Inc., is a publicly traded company engaged in the development of oral drug delivery systems – most notably an oral insulin capsule for treating type 2 diabetes. The company was founded in 2006 and is headquartered in Jerusalem. Its shares are listed on the NASDAQ Capital Market and the Tel Aviv Stock Exchange.
Source: Wikipedia (CC BY-SA 4.0) · copied on Sep 3, 2026 · may not reflect recent changes.
The 25 most recent filings (of 849)
Every SEC filing, newest first, with what it is. Below, each type with its own explanation.
Notice of proposed sale · 2 Form 144 filingsshow all 2hide
- Oct 1, 26Form 144 ↗Notice of proposed sale
- Oct 1, 26Form 144 ↗Notice of proposed sale
- Sep 17, 268-K ↗Current report · Shareholder vote results
- Aug 14, 26SCHEDULE 13G/A ↗Passive stake · Aquamarine Financial (Cayman) Ltd · 6.0% · event on Jun 30, 26 · amendment
- Aug 10, 2610-Q ↗Quarterly report
- Aug 3, 26DEFA14A ↗Shareholder meeting and votes
- Aug 3, 26DEF 14A ↗Shareholder meeting and votes
- Jul 22, 26SCHEDULE 13D/A ↗Stake with intent to influence · amendment
Notice of proposed sale · 2 Form 144 filingsshow all 2hide
- Jul 1, 26Form 144 ↗Notice of proposed sale
- Jul 1, 26Form 144 ↗Notice of proposed sale
- Jun 30, 268-K ↗Current report · Bylaws or fiscal year change · Other events
- Jun 29, 26SCHEDULE 13G/A ↗Passive stake · Leonard Braden Michael · 2.5% · event on Jun 26, 26 · amendment
- Jun 17, 26SCHEDULE 13D/A ↗Stake with intent to influence · amendment
- May 19, 2610-Q ↗Quarterly report
- May 15, 26SCHEDULE 13G ↗Passive stake · Aquamarine Financial (Cayman) Ltd · 5.1% · event on Jan 14, 26
- May 15, 26NT 10-Q ↗Late filing notice
- May 14, 26Form 3 ↗Insider transaction
849 filings on record, the oldest from Jan 15, 04.
Listing the 25 most recent filings of the 849 on record.
10043
3 material agreements entered2026show all 3hide
- Mar 31, 26Entered a material agreement+1 more in the same filing8-K 1.01 ↗
- Feb 20, 26Entered a material agreement+1 more in the same filing8-K 1.01 ↗
- Jan 14, 26Entered a material agreement+2 more in the same filing8-K 1.01 ↗
- Dec 31, 25A senior executive left or was appointed8-K 5.02 ↗
- Nov 17, 25Entered a material agreement+2 more in the same filing8-K 1.01 ↗
- Oct 24, 25Entered a material agreement+4 more in the same filing8-K 1.01 ↗
- Aug 21, 25A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
9 material agreements entered2024 – 2025show all 9hide
- Jul 23, 25Entered a material agreement+2 more in the same filing8-K 1.01 ↗
- Apr 28, 25Entered a material agreement+2 more in the same filing8-K 1.01 ↗
- Mar 3, 25Entered a material agreement+1 more in the same filing8-K 1.01 ↗
- Feb 27, 25Entered a material agreement+1 more in the same filing8-K 1.01 ↗
- Feb 11, 25Entered a material agreement+2 more in the same filing8-K 1.01 ↗
- Jan 22, 25Entered a material agreement+1 more in the same filing8-K 1.01 ↗
- Jan 3, 25Entered a material agreement+1 more in the same filing8-K 1.01 ↗
- Oct 8, 24Entered a material agreement+3 more in the same filing8-K 1.01 ↗
- Sep 26, 24Entered a material agreement+1 more in the same filing8-K 1.01 ↗
3 senior executive changes2024show all 3hide
- Jun 10, 24A senior executive left or was appointed8-K 5.02 ↗
- May 13, 24A senior executive left or was appointed8-K 5.02 ↗
- Mar 18, 24A senior executive left or was appointed8-K 5.02 ↗
- Mar 18, 24A material agreement was terminated+2 more in the same filing8-K 1.02 ↗
- Jan 23, 24Entered a material agreement+1 more in the same filing8-K 1.01 ↗
- Jan 19, 24A senior executive left or was appointed8-K 5.02 ↗
- Dec 18, 23A senior executive left or was appointed8-K 5.02 ↗
3 material agreements entered2023show all 3hide
- Sep 26, 23Entered a material agreement+3 more in the same filing8-K 1.01 ↗
- Aug 22, 23Entered a material agreement+2 more in the same filing8-K 1.01 ↗
- Aug 9, 23Entered a material agreement+1 more in the same filing8-K 1.01 ↗
The record reaches back to Jun 16, 05.
Corporate events are tracked from 2004-08-23, when the SEC renumbered 8-K items. Earlier filings use an incompatible numbering and are not classified here.
Schedule 13D: stake and stated purpose
Filed by holders above 5% of a share class who cannot use the short form. It includes the investor's stated purpose: read it before assuming they seek influence.
- Nadav Kidron7.6%Feb 11, 25SCHEDULE 13D/A ↗
Schedule 13G: short-form filing
The short form, for holders who meet specific requirements: institutional investors, passive investors without a control purpose, or exempt investors. Asset managers and index funds usually file it.
- BML Investment Partners, L.P.6.5%Dec 31, 24SCHEDULE 13G/A ↗
- Aquamarine Financial (Cayman) Ltd6.0%Jun 30, 26SCHEDULE 13G/A ↗1 earlier filing
- Leonard Braden Michael2.5%Jun 26, 26SCHEDULE 13G/A ↗2 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing
Structured 13D/G data starts 2023-12, when the SEC moved these filings to a machine-readable format. Earlier filings exist but are not parsed here.
Sale intention announced
On Oct 1, Avi Gabay filed notice of intent to sell up to $93K. That is about 0.05% of shares outstanding. It is filed under a scheduled plan (10b5-1), arranged in advance.
A notice is not a sale: it may not go ahead, may happen in part, or at a different price.
After the notice, they sold $90K on Oct 1, per their Form 4. That is 100% of the shares announced so far, and the window is still open.
View notice (Form 144) ↗+3 more recent notices · 3 with a later sale
Stock compensation, tax and giftsshow the 36 other transactionshide
Stock compensation, tax withholding, option exercises and gifts. They are listed separately and are not included in the purchase and sale totals. The type describes the transaction, not the filer's intent.
- Sep 24, 26Compensationamount n/aAvraham GabayChief Financial Officer↗
- Sep 24, 26Compensationamount n/aMiriam KidronChief Scientific Officer↗
- Sep 24, 26Compensationamount n/aMiriam KidronChief Scientific Officer↗
- Sep 24, 26Compensationamount n/aJoshua HexterCOO & CBO↗
- Sep 24, 26Compensationamount n/aJoshua HexterCOO & CBO↗
- Sep 24, 26Compensationamount n/aNADAV KIDRONPresident and CEO↗
- Sep 24, 26Compensationamount n/aNADAV KIDRONPresident and CEO↗
- Jul 2, 26Compensation$185KJoshua HexterCOO & CBO↗
- Mar 30, 26Tax$1.4MMiriam KidronChief Scientific Officer↗
- Mar 30, 26Tax$148KNADAV KIDRONPresident and CEO↗
- Mar 17, 26Compensationamount n/aAvraham GabayChief Financial Officer↗
- Mar 17, 26Compensationamount n/aJoshua HexterCOO & CBO↗
- Mar 17, 26Compensationamount n/aNADAV KIDRONPresident and CEO↗
- Mar 17, 26Compensationamount n/aMiriam KidronChief Scientific Officer↗
- Mar 12, 26Giftamount n/aNADAV KIDRONPresident and CEO↗
- Jan 22, 26Compensationamount n/aAvraham GabayChief Financial Officer↗
- Jan 22, 26Compensationamount n/aJoshua HexterCOO & CBO↗
- Jan 22, 26Compensationamount n/aMiriam KidronChief Scientific Officer↗
- Jan 22, 26Compensationamount n/aNADAV KIDRONPresident and CEO↗
- Jan 14, 26Giftamount n/aMiriam KidronChief Scientific Officer↗
- Dec 31, 25Compensationamount n/aAvraham GabayChief Financial Officer↗
- Dec 31, 25Compensationamount n/aAvraham GabayChief Financial Officer↗
- Dec 31, 25Compensationamount n/aDaniel Aghion↗
- Dec 31, 25Compensationamount n/aDaniel Aghion↗
- Dec 31, 25Compensationamount n/aArie Mayer↗
- Dec 31, 25Compensationamount n/aArie Mayer↗
- Dec 31, 25Compensationamount n/aBenjamin Shapiro↗
- Dec 31, 25Compensationamount n/aBenjamin Shapiro↗
- Dec 31, 25Compensationamount n/aJoshua HexterCOO & CBO↗
- Dec 31, 25Compensationamount n/aJoshua HexterCOO & CBO↗
- Dec 31, 25Compensationamount n/aMiriam KidronChief Scientific Officer↗
- Dec 31, 25Compensationamount n/aMiriam KidronChief Scientific Officer↗
- Dec 31, 25Compensationamount n/aNADAV KIDRONPresident and CEO↗
- Dec 31, 25Compensationamount n/aNADAV KIDRONPresident and CEO↗
- Dec 31, 25Compensationamount n/aYehuda Reznick↗
- Dec 31, 25Compensationamount n/aYehuda Reznick↗
The full record holds 110 transactions and goes back to Jan 3, 23.
Its sector and its market
Oramed Pharmaceuticals Inc. among Health Care companies
The profile shows what is on record. Context and Radar place the company among those of its sector and region.
Browse its neighbours
Other Health Care companies
With an account you also get
- The four engines — growth, trend, risk and context — each with its word and its score.
- The risk band and the sector phase.
- The company's fundamentals and accounts.
- Watchlist: your list of companies, with the «since you follow it» figure.
The research continues
The profile tells the story. The market sets the scene.
From Oramed Pharmaceuticals Inc., the path continues in the other areas. Each one is shown with its own example, named in its step.
See what deserves a closer look
Every morning Radar screens the covered companies through a lens and explains why each candidate made the list. Public example: the lists from Aug 11, 2026.
See how Radar works →Keep the why
Follow Oramed Pharmaceuticals Inc. in the Watchlist and review what changed since you added it: context, notices and filings. Written theses are coming soon. Public example: Apple.
See an example review →
Coverage
What sits behind this page.
Where each figure comes from and how far it reaches.
- Prices
- End-of-day closes provided by Twelve Data. One close per session; not real time. Closes adjusted for splits.
- Series quality
- 250 clean closes in the period.
- SEC records
- 849 documents on file, from Jan 15, 2004 to Oct 2, 2026.
- Company description
- Wikipedia, read on Sep 3, 2026.
- This page
- Generated on Oct 19, 2026; refreshed through the day.
Start at your own pace
Explore first. Go deeper with access.
Every company's public profile is open. The full reading — context, Radar, watchlist — is inside, in an invitation-only beta.
Compare plans →- No account
This profile for every company we cover: closing prices with the record's facts on the curve, the SEC file in plain language, insider trades included, and links to its sector and exchange.
- Pro
What matters today, with its reason, is free with an account. Pro adds, in the profile, each company's notices and their explanation and the analysis of its insiders; in Radar, all the lenses, which notice each candidate carries, filters by notice type and «no dilution», and the cycle cohort filter; and in Watchlist, more companies and notice changes with their reason.
- Pro+
Adds the Lab: test a hypothesis on comparable cohorts before reusing it; and bring your lenses to Radar.
Are the prices real time?
No. It is one close per session, from the provider and with the date shown on the profile; it does not update during the trading day.
Which SEC documents appear here?
Those filed with the SEC by the company, its insiders and its major shareholders, within our coverage: periodic reports (10-K, 10-Q, 20-F), material events (8-K), proposed sale notices (Form 144), insider transactions (Form 4) and stakes above 5% (13D/13G). Each links to the original on EDGAR.
Why does a European company show no SEC records?
It depends on the company: some European issuers file a 20-F or 6-K with the SEC and others don't. The profile shows whatever is on record; when there is nothing, it says so rather than guessing why. Europe does not yet have a common filing archive like EDGAR in the United States. The EU will open its own, ESAP, in July 2027 (managers' transactions arrive in January 2028), and we plan to add it once it is available.
Before forming a view on a company,
read what is on record.
One close per session. The record in plain language. Its sector and its market one link away. Your judgment when deciding.